{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:52:20Z","timestamp":1782993140879,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.jneuroim.2008.05.022","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T04:12:39Z","timestamp":1217995959000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation"],"prefix":"10.1016","volume":"201-202","author":[{"given":"Talma","family":"Brenner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Nizri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Irony-Tur-Sinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Hamra-Amitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhak","family":"Wirguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2008.05.022_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mus.880150218","article-title":"Guidelines in electrodiagnostic medicine. American Association of Electrodiagnostic Medicine","volume":"15","year":"1992","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib3","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.07.017","article-title":"Are there protective treatments for cognitive decline in MS?","volume":"245","author":"Amato","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib6","series-title":"Handbook of myasthenia gravis","first-page":"295","article-title":"Drugs and the neuromuscular junction: pharmacotherapy and adverse effects in transmission disorders","author":"Argov","year":"1994"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1212\/01.wnl.0000267884.39468.7a","article-title":"Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase","volume":"69","author":"Argov","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0022-510X(02)00069-2","article-title":"Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease","volume":"206","author":"Bjartmar","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neures.2006.01.003","article-title":"Stimulated-single fiber electromyography monitoring of anti-sense induced changes in experimental autoimmune myasthenia gravis","volume":"55","author":"Boneva","year":"2006","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/35013070","article-title":"Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin","volume":"405","author":"Borovikova","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1096\/fj.02-0609com","article-title":"The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis","volume":"17","author":"Brenner","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00023210-200822020-00001","article-title":"Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?","volume":"22","author":"Christodoulou","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib16","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin. Investig."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1056\/NEJMra040223","article-title":"Alzheimer's disease","volume":"351","author":"Cummings","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib18","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.0500073102","article-title":"Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats","volume":"102","author":"D'Intino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-2094-2-4","article-title":"Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures","volume":"2","author":"De Simone","year":"2005","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib20","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1212\/WNL.64.12_suppl_3.S34","article-title":"Diagnosis and treatment of Alzheimer's disease","volume":"64","author":"Desai","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib21","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0306-3623(01)00093-3","article-title":"YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells","volume":"35","author":"Fujii","year":"2000","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1023\/A:1022869222652","article-title":"Cholinesterases: new roles in brain function and in Alzheimer's disease","volume":"28","author":"Giacobini","year":"2003","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1432-1327.1999.00693.x","article-title":"Structural roles of acetylcholinesterase variants in biology and pathology","volume":"264","author":"Grisaru","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrn784","article-title":"New concepts in the immunopathogenesis of multiple sclerosis","volume":"3","author":"Hemmer","year":"2002","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13506120308995249","article-title":"Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease","volume":"10","author":"Hock","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1034\/j.1600-0404.2000.00308.x","article-title":"Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity","volume":"176","author":"Inestrosa","year":"2000","journal-title":"Acta Neurol. Scand., Suppl."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1567205054367928","article-title":"Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway","volume":"2","author":"Inestrosa","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.331.7512.321","article-title":"Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials","volume":"331","author":"Kaduszkiewicz","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/01.wnl.0000269665.62498.5c","article-title":"Restoring balance at the neuromuscular junction","volume":"69","author":"Kaminski","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib31","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0024-3205(03)00068-7","article-title":"The lymphocytic cholinergic system and its biological function","volume":"72","author":"Kawashima","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1474-4422(05)70193-9","article-title":"Symptomatic therapy and neurorehabilitation in multiple sclerosis","volume":"4","author":"Kesselring","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib33","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/01.WNL.0000142989.09633.5A","article-title":"Donepezil improved memory in multiple sclerosis in a randomized clinical trial","volume":"63","author":"Krupp","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1088469","article-title":"Immunotherapeutic approaches to Alzheimer's disease","volume":"302","author":"Monsonego","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI200318104","article-title":"Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease","volume":"112","author":"Monsonego","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/bmj.332.7540.525","article-title":"Diagnosis and treatment of multiple sclerosis","volume":"332","author":"Murray","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","article-title":"Lambert-Eaton myasthenic syndrome","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib38","first-page":"5","article-title":"The emerging diversity of neuromuscular junction disorders","volume":"26","author":"Newsom-Davis","year":"2007","journal-title":"Acta Myol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1411529","article-title":"Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors","volume":"258","author":"Nitsch","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neulet.2004.11.030","article-title":"Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments","volume":"376","author":"Nizri","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.neuropharm.2005.10.013","article-title":"Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors","volume":"50","author":"Nizri","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000097628","article-title":"Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development","volume":"79","author":"Nizri","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.intimp.2007.03.009","article-title":"IBU-octyl-cytisine, a novel bifunctional compound eliciting anti-inflammatory and cholinergic activity, ameliorates CNS inflammation by inhibition of T-cell activity","volume":"7","author":"Nizri","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ana.20454","article-title":"Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production","volume":"57","author":"Pollak","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","article-title":"Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis","volume":"37","author":"Punga","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2007.11.019","article-title":"Role of muscarinic receptors in the regulation of immune and inflammatory responses","volume":"194","author":"Razani-Boroujerdi","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.11.003","article-title":"Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines","volume":"148","author":"Reale","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib48","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.neuropharm.2005.11.006","article-title":"The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients","volume":"50","author":"Reale","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer's disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1471-4159.2004.02347.x","article-title":"Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors","volume":"89","author":"Shytle","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/ni0901-762","article-title":"Multiple sclerosis: a two-stage disease","volume":"2","author":"Steinman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.20913","article-title":"How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis","volume":"60","author":"Steinman","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/WNF.0b013e318059be76","article-title":"Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2","volume":"30","author":"Stip","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.022_bib55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ageing\/afl027","article-title":"Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!","volume":"35","author":"Tabet","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/glia.10132","article-title":"Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes","volume":"41","author":"Teaktong","year":"2003","journal-title":"Glia"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature01339","article-title":"Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation","volume":"421","author":"Wang","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","article-title":"Inflammation in neurodegenerative disease \u2014 a double-edged sword","volume":"35","author":"Wyss-Coray","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.jneuroim.2008.05.022_bib59","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1073\/pnas.162350199","article-title":"Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice","volume":"99","author":"Wyss-Coray","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:09:28Z","timestamp":1759046968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572808002087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":58,"alternative-id":["S0165572808002087"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.022","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}